BeyondSpring, Inc. (BYSI)
| Market Cap | 63.45M |
| Revenue (ttm) | 1.35M |
| Net Income (ttm) | -64.18M |
| Shares Out | 38.93M |
| EPS (ttm) | -1.65 |
| PE Ratio | n/a |
| Forward PE | 10.54 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 191,611 |
| Open | 1.55 |
| Previous Close | 1.59 |
| Day's Range | 1.51 - 1.66 |
| 52-Week Range | 1.13 - 33.00 |
| Beta | 1.03 |
| Analysts | Sell |
| Price Target | 14.61 (+796.3%) |
| Earnings Date | Aug 30, 2022 |
About BYSI
BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and for treatment of later-stage non-small cell lung cancer. It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab, a PD-1 antibody for the treatment of NS... [Read more...]
Financial Performance
In 2021, BeyondSpring's revenue was $1.35 million, an increase of 650.56% compared to the previous year's $180,000. Losses were -$64.18 million, 5.26% more than in 2020.
Financial StatementsAnalyst Forecast
According to 10 analysts, the average rating for BYSI stock is "Sell." The 12-month stock price forecast is 14.61, which is an increase of 796.32% from the latest price.
News
BeyondSpring Presents New Clinical Data in the Chemotherapy-Induced Neutropenia and NSCLC Programs at the 2022 ASCO A...
NEW YORK, May 27, 2022 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a clinical stage global biopharmaceutical company focused on developing innovative cancer t...
BeyondSpring Files 2021 Annual Report on Form 20-F
NEW YORK, April 14, 2022 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (Nasdaq: BYSI), a clinical stage global biopharmaceutical company focused on developing innovative cancer...
BeyondSpring Announces Fourth Quarter and Year End 2021 Financial Results and Provides a Corporate Update
- Company to host call today, April 14, 2022 at 8:00 am ET
BeyondSpring to Announce Fourth Quarter and Year End 2021 Financial Results and Host a Conference Call on Thursday, A...
NEW YORK, April 08, 2022 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therap...
BeyondSpring Cuts On-Third Of Its Workforce
BeyondSpring Inc (NASDAQ: BYSI) plans to reduce its U.S. workforce by 35%, including reassignment of certain personnel to subsidiaries, which is expected to result in cost savings that will extend the c...
BeyondSpring Announces Organizational Streamlining
NEW YORK, Jan. 11, 2022 (GLOBE NEWSWIRE) -- BeyondSpring Pharmaceuticals (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global pharmaceutical company focused on the development of cancer therapeuti...
BeyondSpring Inc. (BYSI) Reports Q3 Loss, Lags Revenue Estimates
BeyondSpring Inc. (BYSI) delivered earnings and revenue surprises of 18.97% and 0.88%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
BeyondSpring Announces Third Quarter 2021 Financial Results and Provides a Corporate Update
- Positive Phase 3 data in 2nd/3rd line NSCLC (Dublin-3): Superior efficacy benefit in plinabulin and docetaxel combination in overall survival, 2-year and 3-year OS rate, PFS, ORR, and significant redu...
BeyondSpring's New Plinabulin Data Shows Fast Onset In Preventing Chemo-Induced Neutropenia
BeyondSpring Inc (NASDAQ: BYSI) announced new data highlighting the mechanism of action of plinabulin in preventing chemotherapy-induced neutropenia (CIN) at the American Society of Hematology (ASH) Ann...
BeyondSpring Pharmaceuticals Announces New Clinical Data Confirming Plinabulin's Fast Onset Mechanism of Action in th...
NEW YORK, Dec. 15, 2021 (GLOBE NEWSWIRE) -- BeyondSpring Pharmaceuticals (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global pharmaceutical company focused on the development of cancer therapeuti...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors BeyondSpring Inc. - BYSI
NEW YORK, Dec. 13, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of BeyondSpring Inc. ("BeyondSpring" or the "Company") (NASDAQ: BYSI). Such investors are advised to ...
BeyondSpring Pharmaceuticals Announces Analysis of New Data on the Plinabulin/Pegfilgrastim Combination in Breast Can...
NEW YORK, Dec. 10, 2021 (GLOBE NEWSWIRE) -- BeyondSpring Pharmaceuticals (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global pharmaceutical company focused on the development of cancer therapeuti...
SHAREHOLDER ALERT: Investigation of BeyondSpring, Inc. Announced by Holzer & Holzer, LLC
Atlanta, Georgia--(Newsfile Corp. - December 2, 2021) - Holzer & Holzer, LLC is investigating whether BeyondSpring, Inc. ("BeyondSpring" or the "Company") (NASDAQ: BYSI) complied with federal securitie...
Why BeyondSpring Shares Are Diving Today
BeyondSpring Inc (NASDAQ: BYSI) is trading significantly lower Wednesday after the company announced it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for the...
BYSI Stock Alert: Bad News From the FDA Has BeyondSpring Tanking Today
BeyondSpring is falling hard after the FDA turned down a once-promising drug candidate. Here's why you shouldn't write off BYSI stock.
BeyondSpring Shares Crater After FDA Rejects Plinabulin Application
The FDA has issued a Complete Response Letter to BeyondSpring Pharmaceuticals Inc's (NASDAQ: BYSI) marketing application seeking approval for plinabulin to prevent chemotherapy-induced neutropenia (CIN)...
BeyondSpring's NDA for CIN treatment 'cannot be approved' in current form, FDA says
BeyondSpring Inc. BYSI, -1.84% said Wednesday that it has received a complete response letter (CRL) from the U.S. Food and Drug Administration, saying the biopharmaceutical company's new drug applicatio...
BeyondSpring Pharmaceuticals to Present at the 4th Annual Evercore ISI HealthCONx Conference
NEW YORK, Nov. 24, 2021 (GLOBE NEWSWIRE) -- BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global pharmaceutical company focused on the development of cancer therapeutics, today announ...
3 Biotech Stocks With Huge Catalysts Incoming
These drugmakers have big events that should occur before the end of 2021.
BeyondSpring Announces First Patient Treated in Phase 2 Study with Plinabulin Combined with Nivolumab + Ipilimumab in...
—The study is conducted by the Big Ten Cancer Research Consortium in up to 26 patients across 7 states in the U.S.
BeyondSpring Pharmaceuticals Announces New Patient-Derived Cancer Model Data for Plinabulin Monotherpy at the AACR-NC...
NEW YORK, Oct. 20, 2021 (GLOBE NEWSWIRE) -- BeyondSpring Pharmaceuticals (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global pharmaceutical company focused on the development of cancer therapeuti...
Why Are BeyondSpring's Shares Plunging Today?
BeyondSpring Pharmaceuticals Inc (NASDAQ: BYSI) shared the final intention-to-treat (ITT) dataset from its DUBLIN-3 Phase 3 trial of plinabulin. The trial evaluated plinabulin combined with docetaxel vs.
Here's why BeyondSpring shares are up more than 25% on Monday
Shares of BeyondSpring Inc (NASDAQ: BYSI) gained more than 200% in August as the pharmaceutical company said its candidate drug (Plinabulin) improved life expectancy for patients with advanced lung canc...
BeyondSpring Pharmaceuticals Announces Positive Final Phase 3 DUBLIN-3 Data with the Plinabulin/Docetaxel Combination...
NEW YORK, Sept. 20, 2021 (GLOBE NEWSWIRE) -- BeyondSpring Pharmaceuticals (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global pharmaceutical company focused on the development of cancer therapeut...
BeyondSpring Presents New Plinabulin Data At ESMO Congress
BeyondSpring Pharmaceuticals (NASDAQ: BYSI) announced new plinabulin data from its chemotherapy-induced neutropenia (CIN) prevention program at the European Society for Medical Oncology (ESMO21) 2021 Co...